Monobind

Executive Summary

Monobind Inc., founded in 1982 and headquartered in Lake Forest, California, is a global manufacturer of in vitro diagnostic (IVD) reagents and instruments, specializing in immunoassay technologies including ELISA and CLIA. The company supplies accurate and reliable diagnostic products supporting clinical laboratories in over 120 countries, with a product portfolio spanning allergy, autoimmune, cardiology, endocrinology, infectious disease, and oncology. As a privately held firm with a four-decade track record, Monobind has built a reputation for quality and consistency in the competitive IVD market. Its established distribution network and broad menu of assays position it as a reliable partner for labs worldwide, particularly in segments requiring high-throughput immunoassay testing. While the company does not disclose financials, its long operational history and global footprint suggest stable revenue generation, likely in the tens of millions of dollars annually. Given the increasing demand for diagnostic testing, especially in emerging economies, Monobind is well-placed to capture growth from both traditional and novel infectious disease and chronic condition screening.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation CLIA analyzer with enhanced throughput60% success
• Q2 2027FDA 510(k) clearance for a novel autoimmune assay panel50% success
• Q3 2026Expansion into point-of-care immunoassay market via strategic partnership40% success